Introduction
Generating strong CTL responses is required for a curative anticancer immune response. Potent activation of CD4+ T helper cells is essential to priming and maintaining that CTL response.
1,2 Dr Ostrand-Rosenberg and colleagues discovered that murine tumor cells converted to the MHC Class II+/Ii-phenotype by transfecting genes of the alpha and beta chains of MHC Class II molecules are: (1) potent stimulators of anti-tumor CD4+ T helper cells and (2) capable of providing protection against challenge with parental tumor. [3] [4] [5] Presumably, peptides processed into the ER for binding to MHC Class I molecules become bound to MHC Class II molecules in the absence of the normally peptide-binding-site-blocking Ii protein. We sought a clinically feasible approach to this novel immunotherapy, avoiding transfection of each patient's tumor cells with genes for her or his autologous MHC Class II molecules. This is carried out converting tumor cells into MHC Class II+/Ii+ cells by transfecting the genes for either the MHC Class II transactivator (CIITA) or IFN-g, both of which induce endogenous MHC Class II molecules and the Ii protein. 6, 7 The mRNA for Ii protein is then suppressed by an antisense method. We have created a potent Ii antisense oligonucleotide that inhibited Ii expression in a variety of cells and generated effective tumor cell vaccines. 8 We have also created several active Ii reverse gene constructs (Ii-RGCs) that inhibited Ii expression in A20 B lymphoma cells in vitro and RENCA renal adenocarcinoma tumors in vivo following transfection. In vivo injection of Ii-RGC resulted in effective intratumoral immunotherapy of renal adenocarcinoma tumors. 9 In order to develop an efficient reagent for inducing MHC Class II+/Ii-tumor vaccine cells either in vitro or in situ, we have exploited the favorable characteristics of adenoviruses as vectors for our genetic constructs. Since their development in the early 1980s, recombinant adenoviruses (rAV) have been used to deliver a wide variety of genes into mammalian cells. 10 Numerous researchers have shown that recombinant advenovirus (rAV) is a very efficient DNA delivery vehicle. [11] [12] [13] Compared to other viral delivery methods, rAV has the advantages of high infection rate (nearly 100% cells can be infected in vitro), wide spectrum of cellular tropism (variety of human and nonhuman cells and tissues), robust growth in the culture, and the capacity to infect mitotically quiescent cells. 14, 15 Since the adenovirus does not integrate into the cellular genome, it cannot be used to make stable cell lines. 16 This is a shortcoming when stable transfection is desired; however, a favorable feature when only transient expression is sought.
Adenoviruses have been widely used to deliver antisense constructs. [17] [18] [19] [20] Here, we created a rAV containing CIITA (rAV/CIITA), IFN-g (rAV/IFN-g), or the combination of IFN-g and an Ii-RGC rAV/IFN-g/Ii-RGC. Using either the rAV/CIITA or rAV/IFN-g to induce MHC Class II expression, plus an Ii-antisense oligonucleotide to suppress Ii, or using rAV/IFN-g/Ii-RGC, we generated MHC Class II+/Ii-MC-38 murine adenocarcinoma cells. Injection of Renca tumor nodules with rAV/Ii-RGC and rAV/CIITA/IFN-g combined with a suboptimal dose of rAV/IL-2 induced a potent antitumor immune response. We have relatively optimized the procedures for creating these cells, which could be potent inducers of anticancer immunity upon in vitro use to prepare cancer cell vaccines, or via direct injection into tumors. A major function of Ii protein is protection of the antigenic peptide binding site on MHC Class II molecules from binding to endogenously derived antigenic peptides at the time of synthesis in the ER. 22 The strategy of creating MHC Class II+/Ii-phenotype is thus of value not only for tumor cell vaccines, but also for dendritic cell and DNA vaccines.
Results

Construction of rAVs containing CIITA, IFN-g, and Ii-RGC
We constructed rAV containing CIITA or INF-g according to the manufacturer's instructions. In order to ensure that each infected cell receives both IFN-g and Ii-RGC genes, we cloned IFN-g and Ii-RGC in one adenoviral sequence-containing plasmid, pQBI/Ad/BN (Figure 1 ). Each class of gene is driven by a different promoter (CMV promoter for IFN-g and RSV promoter for Ii-RGC) in order to avoid promoter competition between these classes. The pQBI/Ad/BN/IFN-g/Ii-RGC was cotransfected with Cla1-digested AV DNA into 293A packaging cells. The resulting rAVs were confirmed by PCR to contain both IFN-g and Ii-RGC along with their promoters and Poly A signals. The rAV containing CIITA or IFN-g genes were also constructed and confirmed to contain the genes. These rAVs were expanded and stored for experiments. rAV containing other gene combinations were also constructed according to these methods. Figure 1 Diagram of IFN-g and Ii-RGC containing plasmid. The fragment containing RSV promoter, Ii-RGC, and poly A signal was generated from RSV.5/Ii-RGC by PCR and the fragment containing CMV promoter, IFN-g, and poly A signal was generated from pCDNA(3)/IFN-g by PCR. These fragments were cloned into pQBI/Ad/BN using Not1 and Xho1 for the Ii-RGC fragment, and Kpn1 and Bgl2 for IFN-g. The resulting plasmid pQBI/Ad/BN//IFN-g/Ii-RGC was used to cotransfect adenovirus packaging cell line 293A with Cla1-digested adenoviral DNA to generate rAV/IFN-g/IiRGC. 
Discussion
The great efficiency of rAV as a gene delivery vehicle has been established in numerous studies.
11,12 rAV infects many cell types, and both dividing and nondividing cells. 13, 14 Its only shortfall is that rAV does not integrate into cellular genomes and, therefore, it is not suitable for creating stably infected cells. However, in our application, transient generation of MHC Class II+/Ii-tumor Established Renca tumors were treated, on day 9, with intratumoral injections of adenoviral vectors given once a day over five consecutive days. The proportion of tumor-free mice at the end of the observation period, on day 64 postcell injection, is reported. Tumor-free mice and naïve mice were challenged with Renca cells on day 64, the proportion of challenge-tumor-free mice by day 24 postchallenge is reported. (Figure 2 ). Even at 3 MOI, nearly 100% of such cells were induced to express MHC Class II molecules (Figure 4) . In all our experiments, we have demonstrated clearly that relatively low MOI of rAV efficiently delivers CIITA and IFN-g genes into MC-38 and Renca tumor cells, with better cell viability than at high MOI. Efficient induction at such a low MOI is a significant advantage in our system because the high concentrations of rAV, currently used by many investigators, might produce relatively larger amounts of viral product, which can disrupt various biological functions of the infected cell including antigen processing and presentation. 21 Our adenoviral vectors are an effective reagent to create MHC Class II+/Ii-tumor cells in vitro. rAVs have been widely used to deliver antisense constructs into cells and gene suppression has been observed to varying degrees both in vitro and in vivo. [17] [18] [19] [20] We previously characterized a potent Ii antisense oligonucleotide, and now showed that it inhibited Ii expression in rAVinduced MHC Class II+/Ii+ cells after intracellular delivery by electroporation (Figure 3) . 8 In order to develop better in vivo Ii suppression reagents, we created Ii-RGC plasmid vectors to produce an antisense RNA that dimerizes with the mRNA for Ii protein, thereby inhibiting Ii protein expression. The Ii-RGC plasmid potently inhibits Ii protein in many cell lines following lipid-mediated transient delivery or stable transfection. 8, 9 In order to take advantage of the high efficiency of gene delivery by rAV, we developed rAVs to deliver Ii-RGCs into cells. MC-38 cells were infected with different concentrations of either rAV//IFN-g/Ii-RGC or rAV// IFN-g. At low concentrations (o10 MOI, Figure 4) , the MHC Class II+/Ii-phenotype was induced in 490% cells with rAV/IFN-g/Ii-RGC, while rAV/IFN-g-transduced cells remained MHC Class II+/Ii+. At a concentration of 3 MOI, almost all cells are MHC Class II+/Ii-. At vector concentrations greater than 10 MOI, Ii protein was not inhibited, probably because Ii proteins are too strongly induced by the greater copy number of IFN-g introduced by higher concentrations of rAV/IFN-g/ Ii-RGC. Our results are consistent with those of others, indicating that adenovirus-mediated delivery of antisense RNA is an efficient and clinical feasible method to specifically induce or suppress gene expression. [17] [18] [19] [20] This is the first report, we know, of a single adenoviral vector delivering an expressible transacting gene and an antisense inhibitory gene. This indicates the feasibility of cloning two or more genes with different functions into one adenoviral vector, thereby creating an effective and convenient tool for research and therapeutic use.
Conversion of tumors into APCs
A potent anticancer immune response was generated in Renca-bearing mice after intratumoral gene therapy with our new adenoviral vectors, which induced MHC Class II+/Ii-phenotype in Renca tumor cells. Injection of Renca tumor nodules with rAV/CIITA/INF-g and rAV/ Ii-RGC combined with a suboptimal dose of rAV/IL-2 induced in a much more potent antitumor immune response in 75% of the mice, compared to a 20% response in mice treated with rAV/CIITA/IFNg+rAV/IL-2+wild-type AV. Indeed, tumor regression was seen in three of four mice treated with Ii-RGC. These data indicate that suppression of Ii protein in MHC Class II-expressing tumors augments vaccine activity. Surviving tumor-free mice rejected Renca tumor challenge, demonstrating that adenoviral gene therapy induced specific antitumor immunity. A repeated experiment with a larger number of mice demonstrated complete antitumor immune response in 60% of the mice, associated with rejection of subsequent Renca tumor challenge, confirming specific antitumor immunity (Table 1) . Our findings are consistent with the observations of Ostrand-Rosenberg and our previous studies that generation of MHC Class II+/Ii-tumor cells potentiates a strong T helper cell response leading to control or rejection of the tumor. [3] [4] [5] 8 It is also possible that tumor-infiltrating dendritic cells (DCs) were also transfected by rAV and modified to express MHC Class II+/Ii-phenotype. These DCs might also engulf tumor antigens released by apoptotic tumor cells and then present them to T helper cells.
The important messages from this study for future clinical applications of these novel reagents are the following. First, higher concentrations of adenovirus are not necessarily better because: (1) high concentration of adenovirus may produce viral proteins which disturb the function of the delivered therapy gene 21 and (2) in this system, low level of CIITA-or IFN-g-induced Ii protein can easily be inhibited by the Ii-RGC. Since Ii protein is always coinduced with MHC Class II molecules by CIITA and IFN-g, Ii-RGC is required to induce the MHC Class II+/Ii-phenotype. 22, 23 The second point is that our method to induce MHC Class II and Ii expression and then to inhibit Ii protein expression through adenoviral vectors offers simplicity for clinical use for generating MHC Class II+/Ii-tumor cell vaccines or directly injecting into tumors in situ to induce a potent CD4+ T helper cell response to tumor antigens. One construct can be used for all patients without considering the MHC Class II allele specificity. One of the major functions of Ii is to protect the antigenic peptide binding site on MHC Class II molecules from binding to endogenously derived antigenic peptides in ER. 22 Suppression of this highly conserved, nonallele-restricted protein allows for novel epitopes to be presented on MHC Class II molecules. The final point is that our strategy for generating MHC Class II+/Ii-phenotype not only serves as a promising tumor therapy, but also as a potent adjuvant to augment the efficacy of attenuated viral vaccines (eg, vaccinia and hepatitis), genetic vaccines, and dendritic cell vaccines.
Materials and methods
Cell lines and antibodies
The MC-38 is a murine colon adenocarcinoma cell line. 24 Renca, a murine renal cell carcinoma line, of spontaneous origin in a BALB/c mouse was maintained in vivo by serial intraperitoneal (i.p.) passages and by in vitro culture. 25 Both cell lines were cultured in DMEM medium supplemented with 10% FCS. Antimurine MHC Class II monoclonal antibody M5/114.15.2 was obtained from the culture supernatant of hybridoma HB120 (ATCC, Rockville, MD, USA) by purification on a protein A affinity column (Pierce, Rockford, IL, USA). 
Plasmids and adenovirus
The pQBI/Ad/BN plasmid was purchased from Quantum Biotechnologies (Montreal, Canada). The pcDNA3.1 plasmid was purchased from Invitrogen (San Diego, CA, USA). RSV.5 plasmid was a gift of Dr Long at NIH. 27 Murine IFN-g cDNA gene was obtained from Dr Ananthaswamy at MD Anderson Medical Center, Dallas, TX, USA. 28 The CIITA cDNA gene in pCEP4 expression plasmid was from Dr Laurie Glimcher. 29 Cla I-digested adenoviral DNA and necessary reagents for making recombinant adenoviruses were purchased from Quantum Biotechnology. rAV/IL-2 was obtained from Transgene (Strasbourg, France). 30 
Plasmid construction
The CIITA gene was already available in the pCEP4 expression vector, driven by a CMV promoter. IFN-g was cloned into pcDNA (3) Generation of recombinant adenoviruses containing CIITA, IFN-g, or both IFN-g and Ii-RGC We then created recombinant adenoviruses containing one gene or gene combinations. All gene(s) (or gene combinations) alone with their promoters and poly A signals were PCR excised and cloned into pQBI/BN vector by standard molecular biology methods. These vectors were cotransfected into 293A adenoviral packaging cells with Cla1-digested adenoviral DNA (the left arm of the virus was deleted to reduce background) according to the manufacturer's instruction. At 3 weeks after cotransfection, resulting plaques were screened by PCR to ensure the presence of the CIITA gene, IFN-g gene, and Ii-RGC genes along with their promoters. The viruses were then expanded and titrated according to the manufacturer's instructions.
Infection of MC-38 cells and Renca cells with recombinant adenoviruses
MC-38 or Renca cells were plated at 5 Â 10 4 cells per well in 24-well plates 18-24 h before infection. The viruses were added at different concentrations, at 24 h after virus infection, 1 ml of fresh medium was added. The culture medium was replaced every 24 h with 2 ml of fresh medium. At various times after infection, the cells were washed, trypsinized, and FACS-analyzed for expression of MHC Class II molecules after staining with rat antimouse I-E k monoclonal antibody M5/114.15.2.
Transfection of MC-38 cells with Ii antisense oligonucleotide with electroporation
After rAV infection, 1-2 Â 10 6 MC-38 cells were trypsinized and washed twice with RPMI 1640 without serum and resuspended in 0.5 ml RPMI 1640 without serum. Cells were transferred into a 4-mm gap electroporation cuvette (BTX, San Diego, CA, USA) and 25 mM (final concentration) of antisense, sense, or mismatch oligonucleotides were added and mixed. The cuvette was placed in ice for 10 min and subjected to electroporation (1250 mF/250 V) with an Electro Cell Manipulator 600 (BTX). The cuvette was then kept in RT for another 10 min, and cells were recultured in six-well plate with complete DMEM medium until the cells were analyzed for the expression of MHC Class II and Ii. particles for rAV/Ii-RGC was used. A subtherapeutic dose of 3.8 Â 10 8 particles for rAV/IL-2 was used. 30 A total of 42 ml were injected in each tumor using 0.3 ml insulin syringes. To keep a constant number of total rAVs particles between treatment groups, in groups not receiving rAV/Ii-RGC, the number of particles was supplemented with wild-type AV. Mice were injected for five consecutive days and monitored for tumor growth. Tumors were measured three times a week with a caliper. Tumor volume was calculated using the formula: 0.5236 Â length Â width Â height.
Immunostaining of cultured cells
